Search Results

Your search for Chase Doyle and Caroline Helwick matches 2 pages

Showing 1 - 2

By Chase Doyle and Caroline Helwick / November 25, 2015

Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD

Discussant Clifford Hudis, MD, Chief of Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York, highlighted neratinib’s benefits while also advocating caution in interpreting the results due to incomplete data, the serious side effect of diarrhea, and the potentially...

breast cancer

By Chase Doyle and Caroline Helwick / November 25, 2015

Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Patients with early-stage HER2-positive breast cancer who received neratinib as extended adjuvant therapy demonstrated improved invasive disease–free survival, with an absolute benefit of 2.3% at 2 years.1 However, these results of the ExteNET trial, previously presented at the 2015 ASCO Annual...

Jan

Today In Oncology

Search Results

Your search for Chase Doyle and Caroline Helwick matches 2 pages

Expert Point of View: Clifford Hudis, MD, Shanu Modi, MD, and Richard Gelber, PhD

Neratinib Improves Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Integrated Palliative and Oncology Care for Patients Receiving Treatment for Acute Myeloid Leukemia

Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma

Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer

Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy

Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer